{
  "url": "https://www.law.cornell.edu/regulations/new-york/10-NYCRR-1004.11",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 10 ยง 1004.11 - Manufacturing requirements for approved medical marihuana products",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 10 ยง 1004.11 - Manufacturing requirements for approved medical marihuana products\n\nState Regulations\n(a) Definitions. Wherever used in this Part, the following terms shall have\nthe following meanings: (1)\n\nApproved medical marihuana product\nis the final manufactured\nproduct delivered to the patient that represents a specific brand with a\ndefined cannabinoid content and active and inactive ingredients, prepared in a\nspecific dosage and form, to be administered as recommended by the\npractitioner. (2)\n\nBrand\nmeans a defined medical marihuana product that has a\nhomogenous and uniform cannabinoid concentration (total THC and total CBD) and\nproduct quality, produced according to an approved and stable processing\nprotocol and shall have the same inactive ingredients as that defined for that\nform of the brand. (3)\n\nForm\nof medical marihuana shall be a type of a medical\nmarihuana product approved by the commissioner and shall refer to the final\npreparation of an approved medical marihuana brand; for example, an extract in\noil for sublingual administration, an extract for vaporization or an extract in\na capsule for ingestion. (4)\n\nLot\nmeans a quantity of a medical marihuana extraction product\nthat has a homogenous and uniform cannabinoid concentration and product\nquality, produced according to an approved and stable processing protocol\nspecific to that brand and form of medical marihuana product, during the same\ncycle of manufacture. (5)\n\nLot unique identifier (lot number or bar code)\nmeans any\ndistinctive combination of letters, numbers, or symbols, or any combination of\nthem, from which the complete history of manufacturing, testing, holding, distribution or recall of a lot of medical marihuana product can be\ndetermined. (6)\n\nManufacturing\nshall include, but not be limited to\ncultivation, harvesting, extraction (or other processing), packaging and\nlabeling. (b) A\nregistered organization shall use either carbon dioxide (CO, super-critical) or\nalcohol for cannabinoid extraction and shall only perform extraction of the\nleaves and flowers of female marihuana plants. A registered organization shall\nonly use carbon dioxide that is of a supply equivalent to food or beverage\ngrade of at least 99.5 percent purity; and alcohol used shall be of a grade\nthat meets or exceeds specifications of official compendiums as defined in\nsection\n321\nof title 21 of the United States Code\n(USC). 21 USC section\n321\nis available for copying and inspection\nat the Regulatory Affairs Unit, New York State Department of Health, Corning\n\nTower, Empire State Plaza, Albany, NY 12237. A registered organization shall\nobtain prior written approval from the department if it seeks to use other\nextraction methods. (c) A\nregistered organization shall only produce such forms of medical marihuana as\napproved by the department according to the following requirements: (1)\n\nEach registered organization may\ninitially produce up to five brands of medical marihuana product with prior\napproval of the department. These brands may be produced in multiple forms as\napproved by the commissioner. Thereafter, additional brands may be approved by\nthe department. (2)\n\nEach medical\nmarihuana product brand, in its final form, shall be defined as having a\nspecific concentration of total Tetrahydrocannabinol (THC) and total\n\nCannabidiol (CBD) and shall have a consistent cannabinoid profile. The\nconcentration of the following cannabinoids, at a minimum, must be reported: (i) Tetrahydrocannabinol (THC); (ii)\n\nTetrahydrocannabinol acid\n(THCA); (iii)\n\nTetrahydrocannabivarin (THCV); (iv)\n\nCannabidiol (CBD); (v) Cannabinadiolic acid (CBDA); (vi)\n\nCannabidivarine (CBDV); (vii)\n\nCannabinol (CBN); (viii)\n\nCannabigerol (CBG); (ix)\n\nCannabichromene (CBC); (x) Any\nother cannabinoid component at > 0.2 percent, for which there is a certified\nstandard available at a customary cost. (3)\n\nThe final medical marihuana product shall\nnot contain less than 90 percent or more than 110 percent of the concentration\nof total THC or total CBD indicated on the label for this brand and shall have\nno more than 10mg total THC per dose. However: (i) Where\nthe total THC concentration is less than 5 milligrams per dose, the\nconcentration of total THC shall be within 0.5 milligrams per dose; (ii)\n\nWhere the total CBD concentration is\nless than 5 milligrams per dose, the concentration of total CBD shall be within\n0.5 milligrams per dose; and\n(iii)\nthe concentration of total THC and CBD in milligrams per single dose for each\nsample of a brand lot submitted for testing must be within 25 percent of the\nmean concentration of total THC and CBD in milligrams per single dose for that\nsubmitted lot with the exception that, for brands with a specified total THC\nand CBD concentration less than 2 milligrams per single dose, the concentration\nof each sample for that low concentration cannabinoid shall be within 0.5\nmilligrams per dose of the mean concentration. (4)\n\nThe registered organization shall offer\nand make available to patients at least one brand that has a low THC and a high\nCBD content (\ne.g., a 1:20 ratio of THC to CBD). (5)\n\nThe registered organization shall offer\nand make available at least one brand that has approximately equal amounts of\nTHC and CBD. (6)\n\nFor each brand\noffered, the registered organization shall only utilize a distinct name which\nhas been approved by the department, consisting of only letters and/or numbers. The name shall not be coined or fanciful, and may not include any street, slang\nor other name. No reference shall be made to any specific medical\ncondition. (7)\n\nEach registered\norganization shall ensure the availability of at least a one year supply of any\noffered brand unless otherwise allowed by the department. (d) The registered organization shall not add\nany additional active ingredients or materials to any approved medical\nmarihuana product that alters the color, appearance, smell, taste, effect or\nweight of the product unless it has first obtained prior written approval of\nthe department. Excipients must be pharmaceutical grade and approved by the\ndepartment. (e) A registered\norganization shall: (1)\nuse good agricultural\npractices (GAPs) and must conform to all applicable laws and rules of New York\n\nState; (2)\nuse water from a public\nwater supply or present a plan, approved by the department, which demonstrates\nthe ability to obtain sufficient quantities of water of equal or greater\nquality as that from a public water supply and to monitor the quality of such\nwater on an ongoing basis; (3)\nupon\nprior written notice to the department, only use pesticides that are registered\nby the New York State Department of Environmental Conservation or that\nspecifically meet the United States Environmental Protection Agency\nregistration exemption criteria for Minimum Risk Pesticides, and only in\naccordance with section\n325.2(b)\nof title\n6 of the NYCRR; (4)\nprocess the\nleaves and flowers of the female plant only, in a safe and sanitary\nmanner; (5)\nperform visual\ninspection of the harvested plant material to ensure there is no mold, mildew, pests, rot or gray or black plant material; (6)\nhave a separate secure area for temporary\nstorage of any medical marihuana or medical marihuana product that needs to be\ndestroyed; and\n(7)\nprovide\ncontinual environmental monitoring for temperature, ventilation and humidity at\nall locations in the manufacturing facility where unprocessed leaf and flower\nmaterial is stored, until further extraction or other processing is\ncompleted. (f) Production\nof any approved medical marihuana product shall be in accordance with general\nsanitary conditions. Poisonous or toxic materials, including but not limited to\ninsecticides, rodenticides, detergents, sanitizers, caustics, acids and related\ncleaning compounds must be stored in a separate area from the marihuana and\nmedical marihuana products in prominently and distinctly labeled containers, except that nothing herein precludes the convenient availability of detergents\nor sanitizers to areas where equipment, containers and utensils are washed and\nsanitized. (g) Approved medical\nmarihuana products shall be limited to the forms of administration approved by\nthe Department, including but not limited to: (1)\nmetered liquid or oil\npreparations; (2)\nsolid and\nsemisolid preparations (e.g. capsules, chewable and effervescent tablets, lozenges); (3)\nmetered ground plant\npreparations; and\n(4)\ntopical forms\nand transdermal patches. (5)\nmedical marihuana may not be incorporated into food products by the registered\norganization, unless approved by the commissioner. (6)\n\nSmoking is not an approved route of\nadministration. (h) The\nregistered organization shall package the final form of the approved medical\nmarihuana product at the manufacturing site. The original seal shall not be\nbroken except for quality testing at an approved laboratory, for adverse event\ninvestigations, by the department, or by the certified patient or designated\ncaregiver, or by the registered organization for internal quality control\ntesting or disposal. (i) The\nregistered organization shall package the approved medical marihuana product\nsuch that it is child-resistant, tamper-proof/tamper-evident, light-resistant, and in a resealable package that minimizes oxygen exposure. (j) The registered organization shall\nidentify each lot of approved medical marihuana product with a lot unique\nidentifier. (k) Each approved\nmedical marihuana product shall be affixed with a product label. Medical\nmarihuana product labels shall be approved by the department prior to use. Each\nproduct label shall be applied at the manufacturing facility, be easily\nreadable, firmly affixed and include: (1)\nthe\nname, address and registration number of the registered organization; (2)\nthe medical marihuana product form and\nbrand designation; (3)\nthe single\ndose THC and CBD content for the product set forth in milligrams\n(mg); (4)\nthe medical marihuana\nproduct lot unique identifier (lot number or bar code); (5)\nthe quantity included in the\npackage; (6)\nthe date\npackaged; (7)\nthe date of\nexpiration of the unopened product, based on stability studies in accordance\nwith section\n1004.11\n(m)(2)\nof\nthis title, or a tentative expiration date approved by the\ndepartment; (8)\nthe proper storage\nconditions; (9)\nlanguage stating: (i) \"Medical marihuana products must be kept\nin the original container in which they were dispensed and removed from the\noriginal container only when ready for use by the certified patient\"; (ii)\n\"Keep secured at all times\"; (iii)\n\"May not be resold or transferred to\nanother person\"; (iv)\n\"This product\nmight impair the ability to drive\"; (v) \"KEEP THIS PRODUCT AWAY FROM CHILDREN\n(unless medical marihuana product is being given to the child under a\npractitioner's care\"); and\n(vi)\n\"This product is for medicinal use only. Women should not consume during\npregnancy or while breastfeeding except on the advice of the certifying\npractitioner, and in the case of breastfeeding mothers, including the infant's\npediatrician.\"\n(l) For each lot of medical marihuana product\nproduced, the registered organization shall submit a predetermined number of\nfinal medical marihuana products (\ne.g., sealed vials or\ncapsules; with the number of samples submitted, based on statistical analysis, determined to be representative of the lot) to an independent\nlaboratory/laboratories approved by the department. The laboratory verifying\nthe cannabinoid content shall be approved for the analysis of medical marihuana\nproduct by the department in accordance with section\n502\nof the\n\nPublic Health Law and Subpart 55-2 of this Title. Such laboratory, or approved\nlaboratories cumulatively, shall certify the medical marihuana product lot as\npassing all contaminant testing and verify that the content is consistent with\nthe brand prior to the medical marihuana product being released from the\nmanufacturer to any dispensing facility. (1)\n\nAny lot not meeting the minimum standards or specifications for safety shall be\nrejected and destroyed by the registered organization in accordance with\nsection\n1004.24\nof this Part. (2)\n\nAny lot not meeting the minimum standards\nor specifications for brand consistency shall be reported to the department and\nnot dispensed by a registered organization without prior written approval from\nthe department. (3)\n\nThe registered\norganization shall keep and maintain records documenting submission of medical\nmarihuana products to approved laboratories as required herein, and the results\nof the laboratory testing. The registered organization shall provide the\ndepartment with such records upon request. (m) The registered organization shall\ndemonstrate the stability of each approved medical marihuana product produced\n(each brand in each form) by testing both the unopened and opened product at an\napproved laboratory in accordance with section\n1004.14\n(h) of\nthis Title: (1)\nthe stability of opened\nproducts shall be validated under the conditions (light, temperature and\nhumidity), specified for storage of the product and an expiration date for\nopened product shall be determined; (2)\nthe stability of unopened products\n(\ne.g., sealed packages or vials) shall be validated by ongoing\nstability testing and an expiration date for unopened products shall be\ndetermined. (3)\nspecifications\nregarding storage conditions must address storage at the manufacturing facility\nonce the package is sealed, during transport, at the dispensing facility, in\nthe patient's home and for samples retained for future testing. (n) No synthetic marihuana\nadditives nor any cannabinoid preparation not produced by a registered\norganization in an approved manufacturing facility shall be used in the\nproduction of any medical marihuana product; provided, however, that a\nregistered organization may use hemp, or extracts derived from hemp, grown and\nprocessed under the authority of the New York State Department of Agriculture\nand Markets in the manufacturing of medical marihuana products. (o) The registered organization's approved\nstandard operating procedure for the aforementioned activities must be\nfollowed, unless otherwise approved by the department. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 10\nยง\n1004.11\n\nAdopted, New\n\nYork State Register April 15, 2015/Volume XXXVII, Issue 15, eff. 4/15/2015\n\nAmended\n\nNew\n\nYork State Register December 27, 2017 /Volume XXXIX, Issue 52, eff. 12/27/2017\n\nAmended\n\nNew\n\nYork State Register February 26, 2020/Volume XLII, Issue 08, eff. 2/26/2020\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 13933
}